Comparative Pharmacology
Head-to-head clinical analysis: METATENSIN 2 versus SER AP ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METATENSIN 2 versus SER AP ES.
METATENSIN #2 vs SER-AP-ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
SER-AP-ES is a combination product containing reserpine (depletes catecholamines from adrenergic nerve endings), hydralazine (direct vasodilation via smooth muscle relaxation), and hydrochlorothiazide (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
SER-AP-ES is a combination antihypertensive tablet containing reserpine 0.1 mg, hydralazine hydrochloride 25 mg, and hydrochlorothiazide 15 mg. Usual adult dose: one tablet orally twice daily. Increase as needed to a maximum of two tablets twice daily.
None Documented
None Documented
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
Reserpine: 50-100h (terminal); hydralazine: 2-8h (slow acetylators 4-8h, fast 2-4h); hydrochlorothiazide: 6-15h. Context: reserpine's long t½ accounts for prolonged effects; hydralazine requires dose adjustment for acetylator status.
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Renal: 30-40% unchanged reserpine; 60-70% as metabolites (hydralazine: 50% renal, 15% fecal; hydrochlorothiazide: 95% renal unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination